secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001213900-25-098205
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed appoints Neil Klompas to board, effective October 9, 2025
---------------------------------------------------------------

- Neil Klompas, CPA, CA, appointed to Board; board size increased to 5 members.
- Klompas brings 30+ years experience; was President/COO and CFO at Zymeworks (NASDAQ: ZYME), led 2017 IPO.
- Currently CEO of Augerex Life Science Corp, serves on boards of NervGen Pharma (TSXV: NGEN) and HTuO Biosciences.
- He will receive standard non-employee director compensation: US$50k annual retainer plus potential committee fees.
- No related party transactions or family relationships with any director or officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025098205/0001213900-25-098205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390025098205/ea0260877-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-098205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer